Remix Therapeutics Appoints Robert Gagnon as Chief Financial Officer Portfolio News / By Karina Tin March 22, 2023
Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress Portfolio News / By Karina Tin March 22, 2023
Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479 Portfolio News / By Karina Tin March 20, 2023
Escient Pharmaceuticals Announces Presentation of Data Demonstrating Efficacy of EP262 in a Mouse Model of Atopic Dermatitis at the American Academy of Dermatology Annual Meeting Portfolio News / By Karina Tin March 16, 2023
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates Portfolio News / By Karina Tin March 16, 2023
RAPT Therapeutics Reports Fourth Quarter and Year End Financial Results Portfolio News / By Karina Tin March 14, 2023
Ribon Therapeutics Doses First Patient In Phase 1 Clinical Study with RBN-3143 in Patients with Moderate to Severe Atopic Dermatitis Portfolio News / By Karina Tin March 9, 2023
eFFECTOR Therapeutics to Collaborate with Stanford Medicine on Investigator-Initiated Randomized Phase 2 Study in Patients with ER+ Breast Cancer Portfolio News / By Karina Tin March 8, 2023
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update Portfolio News / By Karina Tin March 8, 2023
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Portfolio News / By Karina Tin March 8, 2023
